Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program


Related Publications

Smolina K, Weymann D, Morgan S, Ross C, Carleton B. Association between regulatory advisories and codeine prescribing to postpartum women. Journal of the American Medical Association. 2015;313(18):1861-2.
Suter E, Misfeldt R, Mallinson S, Wilhelm A, Boakye O, Marchildon G, et al. Comparative Review of the Policy Landscape of Team-based Primary Health Care Service Delivery in Western Canada. Alberta Health Services; 2014.
Laberge M, Pang J, Walker K, Wong ST, Hogg W, Wodchis WP. QUALICOPC (Quality and Costs of Primary Care) Canada: A focus on the aspects of primary care most highly rated by current patients of primary care practices. Ottawa, ON: Canadian Foundation for Healthcare Improvement; 2014.
McGregor MJ, Abu-Laban RB, Ronald L, McGrail KM, Andrusiek D, Baumbusch J, et al. Nursing Home Characteristics Associated with Resident Transfers to Emergency Department. Canadian Journal on Aging. 2012;33(1):38-48.

Publication Topics

Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program

Publication TypeJournal Article
Year of Publication1993
AuthorsAnderson GM, Kerluke KJ, Pulcins IR, Hertzman C, Barer ML
JournalInquiry : a journal of medical care organization, provision and financingInquiry
Pages199 - 207
Date Published1993
KeywordsAge Factors, Aged, British Columbia/epidemiology, Cost Sharing, Drug Costs, Drug Prescriptions/economics/statistics & numerical data, Drug Utilization/economics/statistics & numerical data/trends, Health Expenditures/statistics & numerical data/trends, Humans, Insurance, Health, Reimbursement/economics/statistics & numerical data/trends, Insurance, Pharmaceutical Services/economics/statistics & numerical data/utilization
AbstractThis paper uses claims data from the prescription drug program for the elderly in British Columbia to describe temporal trends in prescription drug use and the determinants of those trends. Drug expenditures under the program increased by 317% from $21.6 million in 1981-82 to $90 million in 1988-89. Of the $68.4 million-dollar increase in overall expenditures, 34% was due to new drugs, 24% to increased age-specific utilization rates of old drugs, 21% to increased prices of old drugs, and 14% to the increased size of the elderly population. The analysis indicates that 61.5% of new drug expenditures can be attributed to four specific drugs and that the relative importance of price and utilization rates in determining changes in expenditures on old drugs varies by drug category. The paper provides a framework for understanding and predicting expenditures for drug benefit plans.
Citation Key255